Sterilisation Validation and Biocompatibility: Evidence Route

1. Key takeaways

Cambodia has no published, class-specific mandatory list for sterilisation and biocompatibility; both requirements are delivered through the technical evidence chain of the CSDT:

• Any device supplied in a sterile state must provide sterilisation validation evidence in Module D (design verification and validation);
• Any device that contacts the human body must provide biocompatibility evaluation evidence and list the material inventory under the materials item of Module C, closing the loop.

The internationally customary evidence route is: ethylene oxide sterilisation per ISO 11135, radiation sterilisation per ISO 11137, and biological evaluation per the ISO 10993 series. None of these standards is Cambodian legislation; they are the natural choice under the ‘conformity with recognised standards’ evidence method recognised by CSDT Module B.

The evidence-chain framing has a practical consequence for planning. Because neither requirement is delivered by a Cambodian-specific test, the work done for other markets is largely reusable — a sterilisation validation and a biological evaluation prepared for another jurisdiction can serve in Cambodia, provided the cited standards remain current editions and the material list they rely on matches the Module C inventory. What Cambodia adds is the obligation to close the loop inside its own dossier structure: the evidence must be findable under the two modules named above, not merely exist somewhere in the company’s files.

GRZAN note: sterilisation and biocompatibility are evidenced through 2 CSDT modules (the materials item of Module C and the verification and validation of Module D); 3 standard families are in common use: ISO 11135 (ethylene oxide), ISO 11137 (radiation), ISO 10993 (biological evaluation).

2. Legal basis

3. Expert insights

1. Cambodia follows the ‘essential principles + recognised standards’ evidence route rather than a ‘designated standards list’ route. This differs from markets that enumerate in writing the standards that must be used. Companies may choose their own evidence method, but — as article 18 of this series explains — citing recognised international standards offers the strongest traceability, so the ISO/IEC series should still dominate in practice. Choosing an ‘in-house industry method’ requires a complete methodological description and costs more.

1. Biocompatibility evaluation must cover two dimensions: nature of contact plus duration of contact. The evaluation endpoints under ISO 10993 depend on the nature of the device’s contact with the body (surface contact, externally communicating, implant) and its duration (short-term, long-term, permanent). The material list in Module C, the evaluation report in Module D and the service-life statement on the labelling must agree on both dimensions.

1. Sterilisation validation has knock-on effects on the sterile barrier system and shelf life. Sterilisation validation proves not only that the sterilisation process works; it also underpins the integrity of the sterile barrier system and the labelled shelf life. It is therefore the same body of evidence as the stability data in article 27 of this series, put to two uses, and should be planned together to avoid duplicate testing.

1. The absence of a Cambodian designated-standards list shifts the burden of edition control to the applicant. Because the reviewer has no published checklist against which to pre-clear standards, the cited standards themselves become the object of review: their titles, editions and scope statements must show that they cover the activity performed. Citing an edition that has been superseded, or a standard whose scope does not match the test actually run, weakens the evidence even when the underlying work is sound. Keeping a standards register with edition dates, and checking it at submission, protects the whole chain built on it.

1. Sequencing these test programmes independently is a common failure mode. When sterilisation validation and biological evaluation are commissioned by different teams on different schedules, the material grades tested in the biological evaluation can drift from the grades finally listed in Module C, and the sterilisation site or process can change after the validation was run. Each drift is individually small; together they break the identity links the dossier depends on. Freezing the material list and the sterilisation process before either test programme starts, and treating any later change as a trigger for impact assessment, keeps the chain intact.

4. Practical recommendations

1. Fix the evaluation endpoints with a ‘nature of contact + duration’ matrix before running tests. Drawing the matrix before submitting samples avoids missing items or performing unnecessary ones.
2. The sterilisation validation report must state the sterilisation method, dose/parameters, validation batches and conclusion, and point to the ISO standard numbers. A report without standard numbers weakens the Module B evidence.
3. Schedule sterilisation and stability testing together. The two share samples and time points; joint scheduling can markedly shorten the documentation preparation period.

5. Verification checklist

• □ Whether the product is supplied sterile determined and the sterilisation validation need defined
• □ Sterilisation report states method, parameters, batches, conclusion and ISO standard numbers
• □ Biocompatibility evaluation endpoints fixed by the ‘nature of contact + duration’ matrix
• □ Material names and grades identical between the Module C list and the biocompatibility report
• □ Cited standards confirmed to be the current valid editions
• □ Sterilisation validation and stability testing scheduled together

Regulatory information verified as of 29 October 2026.

In Southeast Asia, GRZAN’s core capabilities focus on three areas. First, tracking the legislative progress of dedicated medical-device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, whereas Cambodia still has no dedicated Medical Device Act; the current rules are pieced together from three layers: the registration-number legal basis provided by the Law on Drug Management 1996 and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 (2012), and the technical framework provided by the ASEAN Medical Device Directive, so compliance certainty is markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Cambodia, handling registration submissions, regulatory communication and post-market reporting obligations, and assisting with the practical arrangements for a Cambodian registered pharmacist and the licence for pharmaceutical import and export enterprises. Third, quality-system and testing support: GRZAN assists in establishing a quality management system conforming to ISO 13485 and in organising the technical dossier under the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com